Rosen C B, Nagorney D M, Wiesner R H, Coffey R J, LaRusso N F
Department of General Surgery, Mayo Clinic, Rochester, MN 55905.
Ann Surg. 1991 Jan;213(1):21-5. doi: 10.1097/00000658-199101000-00004.
Cholangiocarcinoma is more likely to develop in patients with primary sclerosing cholangitis. Our aims were to describe the clinical presentation, course, and management of patients afflicted with both cholangiocarcinoma and primary sclerosing cholangitis and to estimate the prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis. A retrospective analysis was conducted of 30 patients with both primary sclerosing cholangitis and cholangiocarcinoma managed at our institution during an 8-year period. Development of cholangiocarcinoma was heralded by rapid clinical deterioration with jaundice, weight loss, and abdominal discomfort. Cholangiocarcinoma complicating primary sclerosing cholangitis often was detected at an advanced tumor stage, which precluded effective therapy, and overall median survival was 5 months. Earlier recognition and treatment of cholangiocarcinoma in such patients will be necessary to increase survival rates. Seventy patients with primary sclerosing cholangitis were followed prospectively in a clinical trial of medical therapy for an average of 30 months. Twelve patients died and five were found at autopsy to have cholangiocarcinoma. The potential for cholangiocarcinoma to develop in patients with primary sclerosing cholangitis may indicate that liver transplantation should be considered earlier in the course of the disease.
胆管癌更易在原发性硬化性胆管炎患者中发生。我们的目的是描述同时患有胆管癌和原发性硬化性胆管炎的患者的临床表现、病程及治疗情况,并评估原发性硬化性胆管炎患者中胆管癌的患病率。我们对本机构在8年期间收治的30例同时患有原发性硬化性胆管炎和胆管癌的患者进行了回顾性分析。胆管癌的发生以黄疸、体重减轻和腹部不适导致的快速临床恶化为先兆。并发原发性硬化性胆管炎的胆管癌常在肿瘤晚期被发现,这使得有效治疗无法进行,总体中位生存期为5个月。要提高此类患者的生存率,有必要更早地识别和治疗胆管癌。在一项药物治疗的临床试验中,对70例原发性硬化性胆管炎患者进行了平均30个月的前瞻性随访。12例患者死亡,尸检发现5例患有胆管癌。原发性硬化性胆管炎患者发生胆管癌的可能性表明,在疾病进程中应更早考虑肝移植。